English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Dalbavancin is a lipoglycopeptide antibiotic with activity against Grampositive pathogens and a long half-life allowing for weekly dosing. DISCOVER 1 and 2 were identically designed clinical trials of dalbavancin versus vancomycin (VAN) with option to switch to oral linezolid for the treatment of ABSSSI. We evaluated outcomes of ABSSSI in patients treated with VAN by dosing regimen utilized and serum trough concentrations for VAN.

open forum infectious diseases

675Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program